Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 14)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 Pechala's Reports Lubomir Pechala PROTALIX BIOTHERAPEUTICS INC (PLX=US) - REPORT FOR ACTIVE TRADERS 4 $25 View Abstract
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for PLX 13 $25 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala PROTALIX BIOTHERAPEUTICS INC (PLX=US) 12-months forecast 1 $15 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Biotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards. 63 $20 View Abstract
6-Feb-10 Pechala's Reports Lubomir Pechala PROTALIX BIOTHERAPEUTICS INC (PLX=US) 2-weeks forecast 1 $10 View Abstract
6-Feb-10 Reuters Investment Profile N/A Protalix BioTherapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of PROTALIX BIOTHERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
31-Jan-10 Wright Reports N/A Wright Investors Service Comprehensive Report for Protalix Biotherapeutics Inc 41 $65 View Abstract
21-Jan-10 Zacks Investment Research Inc. N/A PROTALIX BIOTHR (PLX) Zacks Company Snapshot 1 $10 View Abstract
11-Jan-10 Wall Street Transcript ,The The Wall St Transcript MONEY MANAGER INTERVIEW: Investing in Mid-Cap Growth - Fred Martin - Disciplined Growth Investors 6 $50 View Abstract
Next 4

Independent Reports (Showing 1 to 10 of 14)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 Pechala's Reports Lubomir Pechala PROTALIX BIOTHERAPEUTICS INC (PLX=US) - REPORT FOR ACTIVE TRADERS 4 $25 View Abstract
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for PLX 13 $25 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala PROTALIX BIOTHERAPEUTICS INC (PLX=US) 12-months forecast 1 $15 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Biotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards. 63 $20 View Abstract
6-Feb-10 Pechala's Reports Lubomir Pechala PROTALIX BIOTHERAPEUTICS INC (PLX=US) 2-weeks forecast 1 $10 View Abstract
6-Feb-10 Reuters Investment Profile N/A Protalix BioTherapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of PROTALIX BIOTHERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
31-Jan-10 Wright Reports N/A Wright Investors Service Comprehensive Report for Protalix Biotherapeutics Inc 41 $65 View Abstract
21-Jan-10 Zacks Investment Research Inc. N/A PROTALIX BIOTHR (PLX) Zacks Company Snapshot 1 $10 View Abstract
11-Jan-10 Wall Street Transcript ,The The Wall St Transcript MONEY MANAGER INTERVIEW: Investing in Mid-Cap Growth - Fred Martin - Disciplined Growth Investors 6 $50 View Abstract
Next 4

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.